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Abstract 
Background: Cystatin C is a new interesting marker of glomerular filtration rate (GFR). However, data 
regarding its bio-logicalVariance are scarce and conflicting. The ability of cystatin C to longitudinally follow 
renal function in patients therefore remains questionable. Methods: 12 healthy subjects (6 men and 6 women) 
were included in the final statistical analysis. Serum creatinine, plasma cystatin C and GFR were measured twice 
after a 1-week interval on the same day, at the same time, and under the same preanalytical and analytical 
conditions. GFR was measured with an iohexol method. Serum creatinine was measured with a compensated 
Jaffé and an enzymatic method. Plasma cystatin C was measured by a particle-enhanced immunonephelometric 
method. Analytical (CVA) and within-subject (CVI) variances were classically calculated. Results: CVA for 
creatinine (Jaffé and enzymatic methods) and cystatin C was 2.5, 0.97 and 1.29%, respectively. CVI was 5.8,5 
and 4.5% for the Jaffé creatinine, enzymatic creatinine and cystatin C determinations, respectively. Conclusion: 
Our study confirms that intraindividual variation of cystatin C and creatinine are similar. Therefore, from a 
biological point of view, cystatin C seems as accurate as creatinine for the longitudinal follow-up of renal 
function in daily clinical practice. 
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Introduction 
Cystatin C and cystatin C-based equations are presented as interesting new biological variables for the detection 
of chronic renal failure and the estimation of glomerular filtration rate (GFR) [1]. Some authors have also 
suggested that cystatin C is of interest as a cardiovascular risk factor [2]. Nevertheless, this new marker is not 
free from criticism. Especially cystatin C concentrations seem to be dependent from thyroid status, steroids 
therapy and even muscular mass [3-5]. Moreover, the majority of the studies on cystatin C were transversal with 
very few longitudinal studies [6]. In the context of longitudinal studies, the determination of the biological 
variation (and especially intraindividual variation) of cystatin C is of importance. Until now, such data in adults 
are scarce and conflicting in the literature [1]. In the most cited article on this topic, Keevil et al. [7] described an 
intraindividual variation (CVI for within-subject variance) as high as 13.3% in healthy adult subjects, although 
others found a CVI of 4.55% [8]. Yet other authors have found CVI under 5%, but the methodologies, when 
described, were different (including non-healthy diabetics for example) [1, 9, 10]. 
The aim of our study was to check and compare intraindividual variation of cystatin C and creatinine in a healthy 
adult population. 
Methods 
Thirteen healthy volunteers participated in the study (nurses and doctors from our dialysis and clinical chemistry 
hospital staffs); 7 men and 6 women, mean age of 38 ± 8 years, were included. They were neither obese nor 
hypertensive and were non-smokers. Samples and GFR measurements were collected twice after a 1-week 
interval at the same time each day (08:00 h). Plasma cystatin C was measured using the particle-enhanced immu-
nonephelometry method provided by Dade-Behring (Marburg, Germany). Serum creatinine was measured by the 
kinetic rate-blanked compensated Jaffé method on Modular and by the Roche enzymatic method on Hitachi 
(Roche Diagnostics, Mannheim, Germany). All samples were conserved at -20°C. The reference method for 
GFR measurement was based on plasma clearance of iohexol [11]. GFR was calculated from two samples at 120 
and 240 min (slope-intercept method) as described by Brochner-Mortensen [12] (all samples were measured in 
duplicate). Subjects were in a fasting condition and invited to drink 1.51 of water over 4 h after the iohexol 
injection. One patient (a 26-year-old male) had a GFR variation of 17% between the two measurements. He was 
interviewed and admitted having done active exercises the evening beforehand in the first, but not in the second 
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week. This probably explains the abnormally high variability of the GFR in this subject. He was then excluded 
from the statistical analysis which finally included 12 subjects (6 men and 6 women). According to Fraser and 




2 was calculated from the difference between duplicate results for each specimen of 
the first week (SDA
 2 = ∑d2/2n, where d is the difference between duplicates, and n is the number of paired 
results). We obtained SDI
2 (and thus CVI) by subtraction of SDA
2 from the observed variance noted within 
subjects between the 2 weeks. 
Results 
Table 1 shows the mean values of serum creatinine, plasma cystatin C and GFR observed during the first week 
of our study and a summary of the CV results. 
Table 1: Summary of the CV results 








Mean 0.93 0.89 0.67 111 
SD 0.19 0.2 0.07 20 
CVA 2.5% 0.97% 1.29%  
CVI 5.8% 5% 4.5%  
The mean and SD values were calculated from the samples of the first week. GFR = Glomerular filtration rate, SD = standard deviation, CVA 
= analytical variance, CVI= within-subject variance. 
Discussion 
The analytical variances (CVA) obtained for creatinine measurement were therefore excellent and similar to those 
usually described in the literature (0.97 and 2.5% for the enzymatic and the Jaffé method, respectively) [1]. With 
the nephelometric method, our CVA for the cystatin C was as low as 1.29%. This is similar to what other authors 
have described [9]. It must be noted that this CVA is slightly better than the CV described with the turbidi-metric 
method [1, 7, 10]. Imprecision for an analytical method can be defined as minimal, desirable or optimal in 
function of the biological variation of the parameter studied (CVA < 0.75, < 0.5 or < 0.25 CVI, respectively) [14]. 
Considering our CVI results, desirable and optimal performances for imprecision of cystatin C with the Dade-
Behring method should be 2.25 and 1.13% respectively. Creatinine determined with the Jaffé method should 
have a desirable and optimal imprecision of 2.9 and 1.45% respectively, whereas the desirable and optimal CV 
of the enzymatic method should be 2.5 and 1.25%. Our analytical data on imprecision show that the performance 
of the Dade-Behring cystatin C (1.29%) and the Jaffé method (2.5%) are comprised between the optimal and 
desirable performance. Performance of the enzymatic method (0.97%) can be considered as optimal. 
CVI observed for creatinine was 5.8 and 5% for the Jaffé and the enzymatic methods, respectively. Once again, 
these results were not different to those found in the literature [1, 7, 10]. For the cystatin C, we found a CVI of 
4.5%. This value is not significantly different to the CVI of the creatinine. Our results are therefore quite 
different to those noted by Keevil et al. [7] who found a CVI as high as 13.3% for the cystatin C. The population 
we studied was relatively similar to that of Keevil et al. (healthy adult subjects), but, contrary to their study, we 
used a nephelometric method for cystatin C measurement (Keevil et al. used a turbidimetric method) but 
analytical differences can, of course, not explain the results obtained in intraindividual variance. More 
importantly, contrary to Keevil et al., we also measured the intraindividual variation of GFR, which was 4.5%. 
The latter is of importance because the high CVI obtained by Keevil et al. may, as suggested by the authors 
themselves, be due to the variance of the GFR itself. The higher CVI for cystatin could thus reflect the better 
relationship between GFR and cystatin than between creatinine and GFR. From this point of view, our results are 
stronger because we have measured the total variance of GFR. This GFR measurement has allowed us to exclude 
patients with a significant GFR variance and to be sure that the intraindividual variation of our renal markers was 
not influenced by an abnormally high variation of the GFR itself, as was the case for one of our subjects. The 
fact that we measure GFR is the strength of our study but it is also the main limitation. Indeed, from a strict point 
of view, CVI must be calculated from ten points with 2-week intervals. Sensu stricto, our study has determined 
the reproducibility of cystatin C more than biological variability. Once again, we do not want to measure 'renal 
function-linked variability' of cystatin C but the true biological variability of this marker which imposes to 
exclude patients with abnormal GFR variability and thus to measure true GFR. However, measuring GFR ten 
times within 2 weeks is practically and ethically impossible (risk of hypersensitivity to iohexol and risk 
associated with numerous phlebotomies), and, as other authors, we have limited our data to two measurements 
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[10]. Our sample may be viewed as limited (n = 13) but our population was homogenous and healthy. Observing 
our CVI results (4.5% for cystatin C and 5% for cystatin C), a more important sample (n = 50) would certainly 
not permit to show a significant difference. Recently, Bandaranayake et al. [8] described CVI of 4.55% for 
cystatin C in healthy subjects using the same methodology as Keevil et al. [7] except that cystatin C was 
measured by immunonephelometry (but once again, the difference in analytical method cannot fully explain the 
difference in intraindividual variability). This last result is thus confirmed by our study where, once again, we 
have the strong advantage to measure the GFR variability. 
From an analytical and biological point of view, our data allow to definitively conclude that plasma cystatin C 
seems at least as good as serum creatinine for the longitudinal follow-up of renal function. Nevertheless, due to 
other potential problems than analytical limitations of this marker [4, 5], the definitive superiority of cystatin C 
over creatinine must still be confirmed notably in longitudinal studies. Moreover, with our data, the critical 
difference (= 2.27 × (CVA
2 + CVI
2)0.5), defined as the smallest change in results which is not due to chance, 
remains relatively high for cystatin and similar to enzymatic creatinine (13 and 14%, respectively). As the 
relationship between GFR and creatinine or cystatin C is exponential, this fact will still be a limitation factor for 
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